Case Report

Rare Strain of *Vibrio cholerae* Septicemia in a Patient with Multiple Myeloma

Deepu Daniel¹ and Sunil Kumar²

¹Broward Health Medical Center, Fort Lauderdale, FL 33316, USA
²Pulmonary/Critical Care Medicine, Broward Health Medical Center, Fort Lauderdale, FL 33316, USA

Correspondence should be addressed to Deepu Daniel; deepudaniel7@yahoo.com

Received 23 May 2015; Revised 18 June 2015; Accepted 25 June 2015

Academic Editor: Mehmet Doganay

Copyright © 2015 D. Daniel and S. Kumar. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. Non-O1/non-O139 is a rare strain of *Vibrio cholera* that has been documented to cause significant morbidity and mortality in the immunosuppressed population. Case Presentation. A patient with multiple myeloma develops non-O1/non-O139 *Vibrio cholera* septicemia, leading to multiorgan failure and ultimately death. Discussion. An exceedingly rare strain of *Vibrio cholera*, non-O1/non-O139, may be an important factor of morbidity and mortality in certain immunosuppressed populations, such as patients with multiple myeloma and malignancies. Conclusion. Bacteremia involving generally noninvasive microbes, such as non-O1/non-O139 *Vibrio cholerae*, can have significant deleterious effects in the immunosuppressed patients as shown by this case report. Physicians need to be more diligent when treating these patients.

1. Introduction

Reported cases of non-O1/non-O139 *Vibrio cholerae* bacteremia are extremely uncommon in the literature [1]. This strain has, on rare occasions, been shown to cause invasive and systemic manifestations beyond the commonly associated gastrointestinal symptoms of diarrhea, nausea, and emesis [2–4]. Bacterial infections, including such rare instances of non-O1/non-O139 *Vibrio cholerae*, are more prone to occur in the immunosuppressed and may carry worse prognoses in this population [5]. One such population of patients is those with multiple myeloma. This case study presents a peculiar incidence of severe sepsis induced by non-O1/non-O139 *Vibrio cholerae* bacteremia in a multiple myeloma patient leading to severe sepsis, pulmonary hemorrhage, and ventilator dependent respiratory failure.

2. Case Presentation

A 54-year-old Haitian male with a past medical history of multiple myeloma diagnosed one year prior was admitted to Broward Health Medical Center due to septic shock and acute renal injury. He had his last chemotherapy session for the multiple myeloma over 3 months ago and was lost to follow-up since that time period. Symptomatically, he was complaining of diffuse abdominal pain, nausea, vomiting, and diarrhea for 3 days after returning from a trip to Haiti.

Initial vital signs included temperature of 102 degrees Fahrenheit, heart rate 90 beats per minute, blood pressure 86/40 mmHg, and oxygen saturation 100% on 2 L/min of oxygen via nasal cannula. Labs showed a white blood cell count of $2.85 \times 10^3 / \mu L$, hemoglobin 8.7 g/dL, hematocrit 25.5%, platelets $43 \times 10^3 / \mu L$, segmented neutrophils 76%, bands 8%, and lymphocytes 12%. Comprehensive metabolic panel showed sodium 144 mmol/L, potassium 3.9 mmol/L, chloride 119 mmol/L, bicarbonate 12 mmol/L, BUN 31 mg/dL, creatinine 3.5 mg/dL, alkaline phosphatase 39 units/L, aspartate aminotransferase 55 units/L, alanine aminotransferase 65 units/L, and albumin 2 g/dL. Initial X-ray and CT of the chest did not indicate any acute infiltrates. A CT of the abdomen showed mild circumferential wall thickening of the colon extending from the cecum to the rectum indicative of colitis. Aggressive IV fluid hydration was initiated and he was
empirically started on piperacillin-tazobactam. Initial blood cultures preliminarily grew gram negative rods, at which time levofloxacin was added to his regimen.

Within 48 hours of admission he began to experience worsening respiratory distress and severe tachypnea, with ABG indices showing a pH of 7.26, pCO$_2$ of 43, pO$_2$ of 64, base excess of (−8), and O$_2$ saturation of 91%. Patient was switched to a nonrebreather. He was found to be fluid over-loaded with a significant positive fluid balance. The patient had to be placed on BiPap and diuresed with bumetanide. Repeat chest X-ray indicated new right upper lobe infiltrates. After being stabilized he was weaned back to 4 L of O$_2$ via nasal cannula.

Blood culture identification showed growth of *Vibrio cholerae* non-O1/non-O139. Based on identification and susceptibility studies, antibiotic treatment was deescalated to intravenous levofloxacin. The bacterial strain was isolated and identified by the Florida Department of Health in Jacksonville, FL.

However, the patient's clinical status once again deteriorated. He began to develop episodes of copious hemoptysis and worsening thrombocytopenia. Intermittent platelet transfusions and a trial of desmopressin were started; however no significant increase in platelet count was seen. Patient's respiratory status continued to worsen through his course progressing to respiratory failure requiring emergent intubation. He continued to have bloody secretions suctioned from the endotracheal tube. Chest X-rays indicated worsening bilateral fluffy infiltrates. In the setting of continued bloody secretions it was felt that the radiological findings may correlate with pulmonary hemorrhage.

Patient was sent to the operating room for tracheostomy placement and oral packing by the otolaryngologist. Secondary to the extensive amount of oropharyngeal bleeding, vaginal pads were required. The patient was also started on aminocaproic acid, a fibrinolytic inhibitor without any significant improvement. He continued to require full ventilator support and was too hemodynamically unstable to attempt weaning from the ventilator. As his clinical status deteriorated further, he became less responsive and comatose. A CT of the brain revealed a 2 cm hemorrhage in the left cerebellum with mild surrounding edema. He later underwent cardiac arrest and was unable to be revived, ultimately succumbing to his illness.

### 3. Discussion

As mentioned earlier, immunosuppressive states such as multiple myeloma and other hematologic malignancies do place patients at an overall increased risk of bacteremia [7–12]. Hypogammaglobulinemia and a decrease in the production of IgA and IgG may lead to an overall increased risk of infection specifically among those with multiple myeloma. These patients are functionally asplenic and are thus susceptible to bacterial infections, particularly encapsulated microbes [13, 14]. However, a non-O1/non-O139 *Vibrio cholerae* infection has rarely been documented. This case showed the deleterious effects of an exceedingly rare bacterium on an immunosuppressed host.

Shelton et al. described a case report of recurrent non-O1 *Vibrio cholerae* bacteremia in a patient with multiple myeloma [15]. The patient had been admitted both instances, approximately one year apart, with symptoms of fever, malaise, and cough. During both instances, patient did not have any gastrointestinal complaints of diarrhea, nausea, or vomiting. Patient had also denied consumption of raw seafood. The blood cultures drawn during both admissions revealed infection with non-O1 *Vibrio cholerae*. Comparison of the two strains of non-O1 *Vibrio cholerae* showed minor differences to each other. Patient was discharged home both instances on oral antibiotic therapy.

Majority of pathogenic *Vibrio cholerae* strains express two “O” antigens,” O1 and O139. Those that do not express these antigens are classified as non-O1/non-O139 *Vibrio cholerae*. The majority of these latter strains are for the most part nonpathogenic. However there has been a minority that has caused significant pandemics and outbreaks [16–20]. Two main virulence factors that are found in O1 and O139 *Vibrio cholerae* are the choler toxin (CT) and toxin coregulated pilus (TCP) [21]. CT is responsible for causing diarrhea whereas TCP functions in allowing the microbe to colonize the colon [22]. However the mechanism of pathogenicity in non-O1/non-O139 *Vibrio cholerae* is less well established.

Dziejman et al. performed genetic analyses on four strains of non-O1/non-O139 *Vibrio cholerae* (AM-19226, AM-15622, MZO-2, and MZO-3) which were isolated from stool studies from patients in Bangladesh in 2001 [23]. Genomic analyses of the AM-19226 strain showed similarities to genes found in *Vibrio parahaemolyticus* that encode for the Type III Secretion System (TTSS). TTSS produces virulence factors in *V. parahaemolyticus*, as well as in several gram negative organisms (i.e., *Salmonella*, *Shigella*, *Vibrio*, *E. coli*, *Pseudomonas*, *Aeromonas*). TTSS found in *Vibrio parahaemolyticus* functions in causing enterotoxicity. This study suggested the possibility that the TTSS gene cluster in AM-19226 would produce similar virulence factors and that similar TTSS clusters may lead to virulence factors in other non-O1/non-O139 strains.

The reported incidence of non-O1/non-O139 bacteremia is very rare in the United States. According to the CDC's 2011 COVIS (Cholera and Other *Vibrio* Illness Surveillance) annual summary, there were only 68 reported cases of bacteremia attributable to non-O1/non-O139 *Vibrio cholerae* in the United States (Table 1 and Figure 1) [6].

One of the most significant cholera outbreaks ever to occur in the western hemisphere occurred in Haiti in 2010. The patient in this case had confirmed to hospital staff that he has been living in Haiti for nearly 6 months prior to his admission. Chin et al., implementing third generation single molecule DNA sequencing, analyzed the genetic sequences of two prominent *Vibrio cholerae* strains isolated during the Haiti outbreak and compared them to strains seen during earlier outbreaks in South Asia and Latin America [24]. Studies indicated that the likely causative strain of the Haiti outbreak was *Vibrio cholerae* El Tor. This was the same strain isolated from Bangladesh in 2002 and 2008.

This patient passed away from severe sepsis, respiratory failure, pulmonary hemorrhage and copious retropharyngeal bleeding exacerbated by unrelenting thrombocytopenia.
Table 1: Reported *Vibrio* cases in the United States in 2011, taken directly from the 2011 COVIS annual report published in the CDC website [6].

| *Vibrio* species                      | Cases | Demographic characteristics | Outcomes |
|--------------------------------------|-------|-----------------------------|----------|
|                                      | N     | Age (years) | % | Median | Range | Male (n/N) | % | Hospitalizations | % | n/N | % | Deaths | % | n/N | % |
| *V. alginolyticus*                   | 156   | 18          | 33 | 2–86   | 118/155 | 76 | 16/146 | 11 | 0/144 | 0 |
| *V. cholerae* (excluding toxigenic O1 and O139)* | 86    | 10          | 48 | 1–85   | 59/86 | 69 | 28/82 | 34 | 3/80 | 4 |
| *Photobacterium damselae* subsp. *damselae* (formerly *V. damselae*) | 7     | 1           | 55 | 6–77   | 4/7 | 57 | 3/6 | 50 | 0/1 | 0 |
| *V. fluvialis*                       | 37    | 4           | 65 | 20–108 | 18/37 | 49 | 18/34 | 53 | 0/33 | 0 |
| *Grimontia hollisae* (formerly *V. hollisae*) | 7     | 1           | 50 | 42–75 | 7/7 | 100 | 4/7 | 57 | 0/6 | 0 |
| *V. parahaemolyticus*                | 334   | 39          | 45 | 1–94   | 225/334 | 67 | 75/315 | 24 | 7/304 | 2 |
| *V. vulnificus*                      | 113   | 13          | 60 | 8–91   | 87/111 | 78 | 89/113 | 87 | 34/108 | 31 |
| Species not identified               | 87    | 10          | 44 | 3–93   | 51/86 | 59 | 19/82 | 23 | 4/78 | 5 |
| Multiple species†                    | 11    | 1           | 52 | 23–80 | 7/11 | 64 | 4/11 | 36 | 0/10 | 0 |
| Total                                | 853   | 100         | 47 | 1–108  | 587/848 | 69 | 272/811 | 34 | 48/785 | 6 |

*Including 86 nontoxigenic *V. cholerae* (non-O1/non-O139 [68 cases], O1 [2 cases], O139 [1 case], and no serogroup specified [2 cases]) and 13 toxigenic *V. cholerae* (O75 [12 cases] and O141 [1 case]).

†The following combinations of *Vibrio* species were isolated from patients infected with multiple species: *V. alginolyticus, V. parahaemolyticus* (3 patients); *V. cholerae* O1, *V. parahaemolyticus* (1 patient); *V. fluvialis, V. parahaemolyticus* (1 patient); *P. damselae subsp. damselae, Vibrio* species not identified (1 patient); *V. fluvialis, V. furnissii* (1 patient); *V. parahaemolyticus, V. vulnificus* (1 patient); *V. cholerae* non-O1/non-O139, *Vibrio* species not identified (1 patient); *V. alginolyticus, Vibrio* species not identified (1 patient); *V. alginolyticus, P. damselae subsp. damselae* (1 patient). None of these are included in the rows for individual species.

Despite aggressive intravenous fluid hydration, appropriate antibiotic therapy, and multiple transfusions of packed red blood cells and platelets, his illness proved fatal. His underlying multiple myeloma was his most significant comorbidity contributing to his unfortunate outcome. Virulence factors produced by this rare strain of *Vibrio cholerae* may have further attributed to his prognosis; however we are unable to definitively make this conclusion at this time. Further studies will be required to identify and study the pathogenicity virulence factors associated with this microbe.
4. Conclusion

In our case report, we described a fatal case of severe sepsis in a patient with multiple myeloma. The patient's clinical course was complicated by his history of multiple myeloma. It is important to reemphasize the rarity of reported cases of bacteremia caused by these strains of bacteria and that the immunosuppressed population is more prone to bacterial infections, including such rare strains.

It is important for physicians to understand the deleterious effects that a generally nonpathogenic strain of bacteria can have on immunosuppressed patients. Physicians need to be vigilant on this particular population of patients to avoid these consequences. Our case was important in reiterating this fact.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] Centers for Disease Control and Prevention (CDC), Non-O1 and Non-O139 Vibrio cholerae Infections, US Department of Health and Human Services, CDC, Atlanta, GA, USA, 2014.

[2] F. M. T. Ulloa, T. L. Porte, J. S. Braun et al., “Acute gastroenteritis caused by a Vibrio cholerae non-O1, non-O139 strain harboring a genetic region homologous to the VpaI-7 pathogenicity Island,” Revista Chilena de Infectologia, vol. 28, no. 5, pp. 470–473, 2011.

[3] Y.-L. Lee, P.-P. Hung, C.-A. Tsai, Y.-H. Lin, C.-E. Liu, and Z.-Y. Shi, “Clinical characteristics of non-O1/non-O139 Vibrio cholerae isolates and polymerase chain reaction analysis of their virulence factors,” Journal of Microbiology, Immunology and Infection, vol. 40, no. 6, pp. 474–480, 2007.

[4] K. K. Tan, K. S. Sin, A. J. Ng, H. Yahya, and P. Kaur, “Non-O1 Vibrio cholerae septicaemia: a case report,” Singapore Medical Journal, vol. 35, no. 6, pp. 648–649, 1994.

[5] J. M. Fernández, M. Serrano, J. J. De Arriba, M. V. Sánchez, E. Escribano, and P. Ferreras, “Bacteremic cellulitis caused by Non-O1, Non-O139 Vibrio cholerae: Report of a case in a patient with hemochromatosis,” Diagnostic Microbiology and Infectious Disease, vol. 37, no. 1, pp. 77–80, 2000.

[6] Centers for Disease Control and Prevention (CDC), COVIS Annual Summary, 2011, US Department of Health and Human Services, CDC, Atlanta, GA, USA, 2011.

[7] J. M. Hughes, D. G. Hollis, E. J. Gangarosa, and R. E. Weaver, “Non-cholera Vibrio infections in the United States: clinical, epidemiologic, and laboratory features,” Annals of Internal Medicine, vol. 88, no. 5, pp. 602–606, 1978.

[8] K. C. Klontz, “Fatalities associated with Vibrio parahaemolyticus and Vibrio cholerae non-O1 infections in Florida (1981 to 1988),” Southern Medical Journal, vol. 83, no. 5, pp. 500–502, 1990.

[9] S. Safrin, J. G. Morris Jr., M. Adams, V. Pons, R. Jacobs, and J. E. Conte Jr., “Non-O1 Vibrio cholerae bacteremia: case report and review,” Reviews of Infectious Diseases, vol. 10, no. 5, pp. 1012–1017, 1988.

[10] M. I. Siegel and A. I. Rogers, “Fatal non-O1 Vibrio cholerae septicemia in chronic lymphocytic leukemia,” Gastroenterology, vol. 83, no. 5, pp. 1130–1131, 1982.

[11] E. Platia and K. L. Vosti, “Noncholera Vibrio septicemia,” Western Journal of Medicine, vol. 132, no. 4, pp. 354–357, 1980.

[12] C. C. Young, Y. C. Chuang, and C. D. Young, “Non-O1 Vibrio cholerae bacteremia: report of two cases,” Kansenshogaku Zasshi, vol. 65, no. 11, pp. 1479–1483, 1991.

[13] L. Cone and I. W. Uhr, “Immunological deficiency disorders associated with chronic lymphocytic leukemia and multiple myeloma,” The Journal of Clinical Investigation, vol. 43, pp. 2241–2248, 1964.

[14] D. R. Jacobson and S. Zolla-Pazner, “Immunosuppression and infection in multiple myeloma,” Seminars in Oncology, vol. 13, no. 3, pp. 282–290, 1986.

[15] C. H. Shelton III, R. L. Martino, and K. M. Ramsey, “Recurrent non-O1 Vibrio cholerae bacteremia in a patient with multiple myeloma,” Cancer, vol. 72, no. 1, pp. 105–107, 1993.

[16] J. G. Morris Jr., “Non-O group 1 Vibrio cholerae: a look at the epidemiology of an occasional pathogen,” Epidemiologic Reviews, vol. 12, pp. 179–191, 1990.

[17] A. Dalsgaard, O. Serichantalergs, A. Forsslund et al., “Clinical and environmental isolates of Vibrio cholerae serogroup O141 carry the CTX phage and the genes encoding the toxin-coregulated pili,” Journal of Clinical Microbiology, vol. 39, no. 11, pp. 4086–4092, 2001.

[18] S. Rudra, R. Mahajan, M. Mathur, K. Kathuria, and V. Talwar, “Cluster of cases of clinical cholera due to Vibrio cholerae 010 in east Delhi,” Indian Journal of Medical Research, vol. 103, pp. 71–73, 1996.

[19] K. Bagchi, P. Echeverria, J. D. Arthur, O. Sethabutr, O. Serichantalergs, and C. W. Hoge, “Epidemic of diarrhea caused by Vibrio cholerae non-O1 that produced heat-stable toxin among Khmers in a camp in Thailand,” Journal of Clinical Microbiology, vol. 31, no. 5, pp. 1315–1317, 1993.

[20] T.-Y. Ou, J.-W. Liu, and H.-S. Leu, “Independent prognostic factors for fatality in patients with invasive Vibrio cholerae non-O1 infections,” Journal of Microbiology, Immunology and Infection, vol. 36, no. 2, pp. 117–122, 2003.

[21] S. M. Faruque, M. J. Albert, and J. J. Mekalanos, “Epidemiology, genetics, and ecology of toxigenic Vibrio cholerae,” Microbiology and Molecular Biology Reviews, vol. 62, no. 4, pp. 1301–1314, 1998.

[22] D. A. Herrington, R. H. Hall, G. Losonsky, J. J. Mekalanos, R. K. Taylor, and M. M. Levine, “Toxin, toxin-coregulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans,” Journal of Experimental Medicine, vol. 168, no. 4, pp. 1487–1492, 1988.

[23] M. Dziejmian, D. Serruto, V. C. Tam et al., “Genomic characterization of non-O1, non-O139 Vibrio cholerae reveals genes for a type III secretion system,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 9, pp. 3465–3470, 2005.

[24] C.-S. Chin, J. Sorensen, J. B. Harris et al., “The origin of the Haitian cholera outbreak strain,” The New England Journal of Medicine, vol. 364, no. 1, pp. 33–42, 2011.